PDCD1 and cancer: We chose to combine patients receiving nivolumab and pembrolizumab because both treatments have the same mechanism of action, since they both interfere with the interaction between PD-1 and PDL-1, an interaction that downregulates T cells, allowing cancer cells to evade immune surveillance [45].